Selectively depolymerized galactomannan polysaccharide

• US 7,893,252 B2
• Filed: 02/25/2008
• Issued: 02/22/2011
• Est. Priority Date: 09/08/2003
• Status: Active Grant

• Current Assignee: Galectin Therapeutics Inc
• Original Assignee: Pro Pharma Pharmaceutical Inc.
• Inventors: Klyosov, Anatole, Platt, David
• Primary Examiner(s): OLSON, ERIC
• Application Number:
  US12/036,608
• Publication Number:
  US 20080207516A1
• Time in Patent Office: 1,093 Days
• Field of Search: None
• US Class Current: 536/114
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4965 Non-condensed pyrazines
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61K 38/2013 IL-2
• CPC Class Codes: A61K 38/208 IL-12
• CPC Class Codes: A61K 38/212 IFN-alpha
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Disclosed herein are compositions and methods for treating diseases such as cancer. The compositions comprise one or more polysaccharides in an admixture with one or more therapeutic agents. This admixture can be administered to a subject in need thereof using any known method of administration. The therapeutic agent, if administered alone, can cause undesirable side-effects in the subject. The polysaccharide component minimizes or eliminates these side effects. The compositions described herein effectuate an enhanced therapeutic effect along with reduced toxicity.

Claims

1. A mixture, comprising

a first component comprising a parenteral administration vehicle,

a second component comprising a homogenous galactomannan oligosaccharide;

Wherein the homogenous galactomannan oligosaccharide has a ratio of mannose to galactose of about 1.7;

1;

Wherein the homogenous galactomannan oligosaccharide consists essentially of galactose and mannose residues; and

wherein the homogenous galactomannan oligosaccharide results from a sufficiently controlled depolymerization of galactomannan so as to result in a homogenous galactomannan polysaccharide having an average molecular weight of about 4,000 to about 60,000 daltons as assayed by GPC-MALLS.

2. The formulation of claim 1, wherein said homogenous galactomannan oligosaccharide is a β

-1,4-D-galactomannan.

3. The formulation of claim 2, wherein said homogenous galactomannan oligosaccharide is (((1,4)-linked β

-D-mannopyranose)₁₇-((1,6)-linked-β

-D-galactopyranose)₁₀)₁₂).

4. The formulation of claim 1, wherein the homogenous galactomannan oligosaccharide is a galectin antagonist.

5. The formulation of claim 1, wherein the homogenous galactomannan oligosaccharide is further comprised of exposed galactose residues capable of interacting with biological targets.

6. The formulation of claim 1, wherein the homogenous galactomannan oligosaccharide is further capable of interacting with regulatory sites in a biological system governed by galactose-specific residues.

7. The formulation of claim 1, wherein the parenteral administration vehicle is an oily vehicle.

8. The formulation of claim 1, wherein the parenteral administration vehicle is an aqueous vehicle.

9. The formulation of claim 1, wherein the parenteral administration vehicle further comprises formulatory agents.

10. The formulation of claim 9, wherein the formulatory agent is a suspending agent.

11. The formulation of claim 9, wherein the formulatory agent is a stabilizing agent.

12. The formulation of claim 9, wherein the formulatory agent is a dispersing agent.